CannTrust Holdings Inc

Most Recent

  • uploads///AdobeStock_
    Company & Industry Overviews

    Top Developments in the Cannabis Industry’s Early Years

    In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.

    By Adam Jones
  • uploads///cannabis _
    Fund Managers

    Could Leon Cooperman Gain from Cannabis Legalization Moves?

    As CNBC reported yesterday, New Jersey legislators unveiled a plan to legalize cannabis (CGC) for adults in the state.

    By Anuradha Garg
  • uploads///Forward EV to Sales Multiple for Cannabis Producers
    Company & Industry Overviews

    What Investors Are Paying for CRON, HEXO, TRST, and Others

    OrganiGram, Supreme Cannabis, and HEXO were trading at a discount to the peer median of 6.8x as of February 22.

    By Adam Jones
  • uploads///Cannabis
    Macroeconomic Analysis

    Gundlach Compares Cannabis to Bitcoin

    Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.

    By Anuradha Garg
  • uploads///
    Miscellaneous

    What Analysts Expect from Trulieve’s Revenue in 2018 and 2019

    On January 14, 2019, Trulieve opened its 24th dispensary in Florida in St. John’s County.

    By Rajiv Nanjapla
  • uploads///CannTrust Analysts NTM Recommendation and Target
    Company & Industry Overviews

    What Analysts Recommend for CannTrust in February

    In February, analysts’ consensus recommendation for CannTrust was a “buy.”

    By Adam Jones
  • uploads///foliage _
    Company & Industry Overviews

    Why CannTrust Is Trending Higher in February

    CannTrust (CNTTF) has returned nearly 75% year-to-date.

    By Adam Jones
  • uploads///
    Company & Industry Overviews

    EV-to-Sales Valuation Multiple: CRON, HEXO, and Others

    Cronos Group was trading at a forward multiple of 39.9x, which increased from 30.3x on January 18.

    By Adam Jones
  • uploads///
    Miscellaneous

    A Look at Curaleaf’s Core Operations and Expansion Plans

    Curaleaf Holdings (CURA) (CURLF) is a vertically integrated cannabis company headquartered in Wakefield, Massachusetts.

    By Rajiv Nanjapla
  • uploads///CRON MO and WEED vesus MJ ETF
    Company & Industry Overviews

    How Altria Aims to Accelerate Cronos Group’s Growth

    Altria’s (MO) experience in the tobacco business could be leveraged to accelerate penetration in the marijuana market.

    By Adam Jones
  • uploads///green _
    Company & Industry Overviews

    Canopy Growth’s Bruce Linton Talks Next Steps for the Industry

    Last week, Canopy Growth CEO Bruce Linton shed light on the next phases for the cannabis industry at the Cantech Investment Conference.

    By Adam Jones
  • uploads///Canna
    Company & Industry Overviews

    Kamala Harris: Presidential Candidate for Legalizing Marijuana

    Senator Kamala Harris, who also announced her 2020 presidential bid, supports legalizing marijuana at a federal level.

    By Adam Jones
  • uploads///Green Growths Premium on Aphria
    Company & Industry Overviews

    Premium on Aphria Vanished, No More ‘Failed Investment’

    With Aphria slightly higher than Green Growth’s offer, the selling point of a 45% premium has vanished.

    By Adam Jones
  • uploads///CNTTF
    Company & Industry Overviews

    CannTrust Holdings’ Stock Grew ~11% Last Week

    On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

    By Daniel Collins
  • uploads///
    Miscellaneous

    A Look at iAnthus Capital’s Strategic Partnerships

    In the third quarter of 2018, which ended on September 30, iAnthus Capital posted revenue of $1.07 million, which represents an increase of 101% from $0.53 million in the second quarter of 2018.

    By Rajiv Nanjapla
  • uploads///Cannabis Stocks and ETF YTD
    Company & Industry Overviews

    Latest Offer: Aphria Urges Investors to ‘Take No Action’

    Aphria urged its shareholders to “take no action” on Green Growth’s offer until the board “has made a formal recommendation to shareholders.”

    By Adam Jones
  • uploads///cannabis _
    Miscellaneous

    How Analysts Rate CRON, APHA, and CNTTF in January

    Cronos Group has gained nearly 33% YTD as of January 22.

    By Adam Jones
  • uploads/// Forward EV to EBITDA Multiple for Cannabis Companies
    Company & Industry Overviews

    What the Valuations of CRON, HEXO, and CNTTF Indicate This Month

    OrganiGram Holdings (OGRMF), CannTrust (CNTTF), and Supreme Cannabis (SPRWF) are all trading at discounts to the industry median at 9.9x, 14.4x, and 9.6x, respectively.

    By Adam Jones
  • uploads/// Forward EV to Sales Multiple for Cannabis Producers
    Company & Industry Overviews

    Valuations of CRON, HEXO, and Others : Which Stocks Look Cheap?

    In this article, we’ll look at the other five stocks that make up the cannabis industry’s median multiple.

    By Adam Jones
  • uploads///weed _
    Company & Industry Overviews

    Big Headlines that Drove Cannabis Stocks Yesterday

    Yesterday, Tilray announced a revenue sharing agreement with ABG (Authentic Brands Group).

    By Adam Jones
  • uploads///CGCs Anticipated Sales
    Company & Industry Overviews

    How Hemp License Sets CGC on a Path to a Billion Dollars in Sales

    In its recent earnings call, Constellation Brands shed some light on Canopy Growth’s sales.

    By Adam Jones
  • uploads///foliage _
    Company & Industry Overviews

    CannTrust Holdings: Analysts Are Mainly Positive in January

    On January 8, CannTrust Holdings’ (CNTTF) stock price closed at $5.63, which is ~3.04% growth from its close of $5.47 on January 7.

    By Daniel Collins
  • uploads///A
    Company & Industry Overviews

    Medical Cannabis Business Could Be a Huge Windfall for Investors

    While recreational cannabis has gained publicity, the medical cannabis business could lead to a huge windfall for investors.

    By Adam Jones
  • uploads///Tilray versus Other Cannabis Stocks
    Company & Industry Overviews

    Why Tilray Had a Stellar 2018

    In September, the US government approved Tilray’s cannabis drug for import for use in clinical trials assessing relief to patients with essential tremors.

    By Adam Jones
  • uploads///evs
    Company & Industry Overviews

    Cronos Group’s Valuation Multiple Rose in December

    Cronos Group’s (CRON) forward EV-to-sales multiple in December rose to 19.9x from 19.7x on November 30.

    By Adam Jones
  • uploads///Graph
    Company & Industry Overviews

    How CannTrust Is Targeting Asia-Pacific and German Markets

    On October 28, CannTrust Holdings (CNTTF) announced a strategic partnership with Australian cannabis producer, Cannatrek.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    CannTrust’s Earnings Are Expected to Grow Rapidly

    In the first nine months of this year, CannTrust Holdings’ (CNTTF) adjusted EBITDA fell 66.79% YoY (year-over-year) to 1.17 million Canadian dollars, and its net income rose 1,793.06% YoY to 11.97 million Canadian dollars.

    By Margaret Patrick
  • uploads///Forward EV to EBITDA Multiple for Cannabis Companies
    Company & Industry Overviews

    Valuations: Cannabis Companies Got Battered

    CannTrust, Supreme Cannabis, HEXO, and Aphria were trading at a discount to their levels in November. Cannabis stocks have gotten cheaper.

    By Adam Jones
  • uploads///Forward EV to Sales Multiple for Cannabis Producers
    Company & Industry Overviews

    Are Cannabis Stocks Trading Cheap?

    OrganiGram (OGRMF) was trading right at the median at a forward EV-to-sales multiple of 4.6x.

    By Adam Jones
  • uploads///CannTrust Analysts NTM Recommendation and Target
    Miscellaneous

    What Analysts Recommend for CannTrust

    CannTrust (CNTTF) reported its earnings last week on November 14.

    By Adam Jones
  • uploads///Earnings Loss Per Share Estimates
    Earnings Report

    Most Cannabis Companies Expected to Report Losses for the Quarter

    Aurora Cannabis is estimated to report a loss per share of 0.07 Canadian dollars, which would be lower than the profit per share of 0.01 Canadian dollars in the corresponding quarter in 2017.

    By Adam Jones
  • uploads///Gross Margins Estimates
    Earnings Report

    Cannabis Companies Are Expected to Report Healthy Gross Margins

    Cannabis companies (HMMJ) are expected to report impressive YoY revenue growth in the most recent quarter.

    By Adam Jones
  • uploads///Organigram Analysts NTM Recommendations and Targets
    Miscellaneous

    Organigram’s Consensus Price Target Rose in August

    Organigram (OGRMF) is among the top gainers compared to cannabis companies (HMMJ) such as Canopy Growth (WEED) (CGC) and Hydropothecary (HYYDF).

    By Adam Jones
  • uploads///marijuana _
    Company & Industry Overviews

    Cannabis Stocks Took a Nosedive Last Week

    Last week, the cannabis sector slipped into negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) fell about 8.8%.

    By Adam Jones
  • uploads///Aphria Analysts NTM Recommendation and Target
    Miscellaneous

    March Analyst Ratings and Price Targets for Aphria

    Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date).

    By Adam Jones
  • uploads///Cronos Group Analysts NTM Recommendations and Targets
    Miscellaneous

    How Analysts’ Price Target and Ratings for Cronos Group Changed in March

    As of March 22, the consensus analyst mean rating on Cronos Group was 2.3, which remained unchanged from the previous month.

    By Adam Jones
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.